Linda,
You're correct, none of us really knows anyone's position just from a particular post. However, in this instance, given all the BS that's been posted on this thread, and the general tone of his posts in the past, I think it's pretty safe to predict the author's inclination. Whether short zonagen or long a competitor, I think the post was a pretty weak, cheap shot - and it's just getting old. If he is a physician, I'd rather hear his opinion of the results of the phase III trials. Instead, he posted on an old study, wasn't even sure if was Zona's, etc., etc - why bother?? To use your term - it was "unreasonable".
I happen to agree that Zona & Vivus are not competitors - but for different reasons than you offer. Actually, I think they are more collaborative in that their eventual users will not overlap and therefore their individual successes will bolster the entire market(a rising tide lifts all boats).
In any event, I meant no disrespect - to him or to you. |
